Bronchodilators in bronchoscopy-induced airflow limitation in allergen-sensitized cats.
This study investigated the effect of bronchoscopy and bronchoalveolar lavage (BAL) on respiratory function, determined by barometric whole-body plethysmography (BWBP), of healthy and allergen-sensitized cats. Furthermore, the efficacy of inhaled bronchodilators in preventing changes in respiratory function was determined. For test 1, 18 healthy experimental cats were investigated on day 1 by BWBP. On day 2, the cats underwent BWBP after sedation (medetomidine), after anesthesia induction (propofol), and after bronchoscopy and BAL. Enhanced pause (Penh) was significantly increased after bronchoscopy and BAL (1.64 +/- 0.17 versus 1.23 +/- 0.07, P < .05). For test 2, 6 cats were sensitized to ovalbumin (OVA), 6 cats were sensitized to Ascaris suum (AS), and 6 cats served as controls. On day 0, OVA- and AS-sensitized cats underwent an inhaled allergen challenge, whereas controls were exposed to saline. On days 1 and 2, the same protocol as described for test 1 was repeated. Post-BAL Penh of the AS-sensitized cats was significantly higher than at test 1 (2.28 +/- 0.22 versus 1.69 +/- 0.33, P < .05) and was correlated with BAL fluid neutrophil count (r = 0.55, P < .05). During tests 3, 4, and 5, the same protocol as used for test 2 was applied to each cat group, with the animals being randomly treated before sedation with inhaled salbutamol (200 microg), ipratropium bromide (40 microg), or a combination of both (200 + 40 microg). Post-BAL Penh of the AS-sensitized group was significantly decreased after the salbutamol + ipratropium bromide treatment (1.56 +/- 0.18 versus 2.28 +/- 0.22, P < .05). This study suggests that bronchoscopy and BAL induce airflow limitation in cats, which is more severe in the presence of lower airway inflammation. Inhaled salbutamol + ipratropium bromide reduce BAL-induced bronchoconstriction in AS-challenged cats and might be recommended as preventive treatment of asthmatic cats undergoing bronchoscopy.
Kirschvink
Nathalie
N
Department for Functional Sciences B41, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium. nathalie.kirschvink@ulg.ac.be
Leemans
Jérôme
J
Delvaux
François
F
Snaps
Fréderic
F
Clercx
Cécile
C
Gustin
Pascal
P
D000420:Albuterol / Q000494:pharmacology; D000818:Animals; D000941:Antigens / Q000276:immunology; D017165:Ascaris suum / Q000276:immunology; D018893:Bronchoalveolar Lavage / Q000009:adverse effects*; D001993:Bronchodilator Agents / Q000494:pharmacology*; D001999:Bronchoscopy / Q000009:adverse effects*; D002371:Cat Diseases / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D002415:Cats / Q000502:physiology*; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000209:etiology / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary; D009241:Ipratropium / Q000494:pharmacology; D010047:Ovalbumin / Q000276:immunology; D010993:Plethysmography, Whole Body / Q000662:veterinary; D012123:Pulmonary Ventilation / Q000187:drug effects*
D000941:Antigens; D001993:Bronchodilator Agents; D010047:Ovalbumin; D009241:Ipratropium; D000420:Albuterol